Acrivon Therapeutics, Inc. (ACRV – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Li Watsek today.

The data set from the double-blind phase of the RewinD-LB trial presented today at ILBDC is now accessible in the Investor section o the CervoMed website https://www.cervomed.com/.

Tatsuya Yoshida, Mikito Takefuji, and Toyoaki Murohara in the Department of Cardiology, Nagoya University Graduate School of Medicine, identified an enzyme, alpha-kinase 2 (ALPK2) that is specifically ...

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS MASITINIB PLATFORMParis, January 29, 2025, 7pm CETAB Science SA (Euronext - FR0010557264 - AB) ...

In cancer-associated cachexia, elevated TNF-α and IL-6 exacerbate muscle and fat loss by regulating multiple metabolic signaling pathways, which could be ameliorated by Z526's suppression of NF-κB ...

A thermal stability-based proteomic analysis identifies cytoplasmic PEBP1 as a mediator of mitochondrial dysfunction-induced stress response, highlighting its potential role in cellular adaptation ...

A "pocket" on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct ...

An enzyme that helps clear damaged mitochondria can act as a molecular switch and potentially prevent neurons from dying.